PROTA THERAPEUTICS PTY LTD
Adam Foley-Comer is an experienced medical executive currently serving as Chief Medical Officer at PROTA THERAPEUTICS PTY LTD since September 2024 and at KAHR-medical Ltd. since November 2017. Prior roles include Senior Medical Director at Quark Pharmaceuticals Inc., where responsibilities encompassed early clinical development activities for siRNA projects, and Medical Director at Wize Pharma Ltd., focusing on ophthalmology strategy and Phase 2 study implementations. Adam also held the position of Medical Director at BioLineRx, providing leadership and medical guidance across clinical teams. Educational qualifications include an MSc in Surgical Science from UCL and a FRCS (Eng) in Surgery from the Royal College of Surgeons.
This person is not in any teams
This person is not in any offices
PROTA THERAPEUTICS PTY LTD
Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel combination probiotic allergen oral immunotherapy treatments. Prota holds an exclusive license to the patented probiotic food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15mwas secured from OneVentures, a leading Australian venture capital investment firm (OneVentures' Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment. This has enabled Prota to advance their clinical program, develop scalable cGMP product manufacturing processes, and initiate discussions with regulatory agencies in the lead up to a planned large-scale pivotal Phase 3 efficacy and safety study for the PRT100 peanut allergy treatment.